
    
      This study is an open-label, one-sequence, three-period study. A total of 16 healthy male
      subjects will be enrolled. In period 1, subjects will be administered midazolam IV 1 mg, and
      co-administration of midazolam IV 1mg and grapefruit juice 500 mL. In period 2, subjects will
      be administered midazolam PO 5 mg, and co-administration of midazolam PO 5mg and grapefruit
      juice 500 mL. In period 3, subjects will be administered clarithromycin 500 mg for 3-days in
      b.i.d regimen prior to admission. Subjects will be administered midazolam IV 1mg and PO 5mg
      after admission.
    
  